Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial

Journal:

Nature Medicine

Published:

2026-06-25

DOI:

10.1038/s41591-026-04471-x

Affiliations:

22

Authors:

32

Go to article

Institutions	Authors	Share
Heidelberg University Hospital at Medical Faculty Heidelberg, Uni Heidelberg, Germany	11.000000 11.000000	0.34
University Hospital of Würzburg (UKW), JMU, Germany	6.000000	0.19
Charité - University Medicine Berlin, Germany	1.500000	0.05
University Hospital Duesseldorf (UKD), Germany	1.000000	0.03
University Medical Center Hamburg-Eppendorf (UKE), UHH, Germany	1.000000	0.03
University Medical Center Schleswig-Holstein - Campus Kiel (UKSH Kiel), Germany	1.000000	0.03
Johnson & Johnson, United States of America (USA)	1.000000	0.03
Johnson & Johnson Consumer France SAS, France	1.000000	0.03
Johnson & Johnson, UK, United Kingdom (UK)	1.000000	0.03
Johnson & Johnson, Belgium, Belgium	1.000000	0.03
Johnson & Johnson, Netherlands, Netherlands	1.000000	0.03
University Medical Center Freiburg, Germany	1.000000	0.03
Klinikum Chemnitz gGmbH, Germany	1.000000	0.03
University Hospital Carl Gustav Carus Dresden, TU Dresden, Germany	1.000000	0.03
DKTK Partner Site Berlin, Germany	0.500000	0.02
Asklepios Klinik Altona, Germany	0.500000	0.02
Asklepios Clinic St. Georg, Germany	0.500000	0.02
TUM University Hospital Klinikum rechts der Isar (MRI), Germany	0.333333	0.01
German Consortium of Translational Cancer Research (DKTK), Germany	0.333333	0.01
Bavarian Cancer Research Center (BZKF), Germany	0.333333	0.01